First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma.
33 previously untreated advanced stage neuroblastoma patients were treated with [131I]meta-iodobenzylguanidine (MIBG). The number of treatments varied between 2 and 7 per patient (mean 3). Toxicity was seldom severe. Only thrombocytopenia WHO-grade 4 was noticed. Response was documented before surgery for the primary tumour was performed. There was one complete response (CR), 18 partial responses (PR), 11 had stable disease (SD) and 3 had progressive disease (PD). After MIBG therapy and surgery, 12 of 33 patients achieved a CR. This approach is feasible, comparable to multidrug chemotherapy in efficacy and less toxic. Long term results are not known yet.
De Kraker
J
J
Emma Kinderziekenhuis/AMC, Amsterdam, The Netherlands.
Hoefnagel
C A
CA
Caron
H
H
Valdés Olmos
R A
RA
Zsiros
J
J
Heij
H A
HA
Voûte
P A
PA
D019797:3-Iodobenzylguanidine; D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007223:Infant; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D007462:Iodobenzenes / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009447:Neuroblastoma / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D013921:Thrombocytopenia / Q000209:etiology; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine